Scroll down to learn more

Cancer immunotherapy activates T cells and B cells that target specific tumor antigens1-3

The activated immune system is primed to recognize tumor antigens expressed by each patient's unique and frequently changing population of cancer cells1

Some activated T cells kill tumor cells directly or indirectly1

Some activated T cells activate B cells, which become antibody-producing plasma cells1

Learn more
by watching Immunotherapy Is Tumor-Specific (2:10)

Immunotherapy Is Tumor-Specific

Scroll down to learn more

Cancer immunotherapy is designed to support the immune system's ability to adapt its attack over time 1,3-6

Each patient's population of tumor cells mutates over
time, which may result in resistance to traditional
anticancer therapies1

When a tumor cell is killed, additional antigens are released, stimulating activation of new populations of
T cells and B cells that recognize tumor antigens1,2,4,5

This can result in an expanding cascade of immune cells
able to recognize cancer cells bearing a variety of tumor antigens as the tumor mutates over time3-6

Learn more by watching Immunotherapy Is Designed to Support Immune System Adaptability (2:43)

Immunotherapy Is Designed to Support Immune System Adaptability

Scroll down to learn more
Immunotherapy for cancer stimulates immunologic memory, which may lead to a prolonged antitumor response1,7-8

Some activated immune cells become
memory cells, which remain primed to stimulate an anticancer immune
response when tumor cells bearing
target antigens are encountered within
the body1,7-8

Learn more by watching Immunotherapy Empowers a Durable Immune Response (2:16)

Immunotherapy Empowers a Durable Immune Response

Learn More About the Immune System and Cancer